Menotrophin Ferring (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After injection, the FSH component stimulates growth of ovarian follicles, while the LH component supports steroid production and luteal phase function. In men, the combined hormones act on the testes to encourage sperm production.

The dose of Menotrophin is individualized. A qualified prescriber determines the amount, frequency and duration of treatment based on the patient’s specific condition, response to therapy and monitoring results. No standard dosing regimen is provided in public information.

Menotrophin is not intended for use during an established pregnancy, and its safety in pregnancy has not been established. It is also not recommended for breastfeeding mothers because the effects on the infant are unknown. Patients should discuss any concerns with their healthcare provider.

To order Menotrophin Ferring, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Menotrophin provides both FSH and LH activity in a single preparation, whereas many newer products offer recombinant FSH or LH alone. The combined formulation can simplify dosing for protocols that require both hormones, but recombinant preparations may have higher purity and lower risk of immunogenicity. Choice of product depends on clinical protocol, patient response and physician preference.

Menotrophin must be stored in a refrigerator at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If the product reaches room temperature for a short period, it may be used, but it should be returned to refrigerated conditions promptly.

Menotrophin is given by subcutaneous or intramuscular injection. The injection site should be rotated to minimise irritation. Healthcare professionals typically reconstitute the powder with the supplied diluent before administration, following aseptic technique and the prescribing information for the exact volume and concentration.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain, fluid accumulation and thromboembolic events, and the increased chance of multiple pregnancy. Rarely, allergic reactions such as anaphylaxis may occur. Patients should be monitored closely for these complications.

Menotrophin is contraindicated in women who are already pregnant, have known hypersensitivity to the product or its excipients, or have uncontrolled thyroid disease. Men with severe hypogonadism unrelated to pituitary deficiency, uncontrolled endocrine disorders, or a history of thromboembolic disease should also avoid its use unless specifically advised by a specialist.